FOXC1 is a potential prognostic biomarker with functional significance in basal-like breast cancer

Partha S. Ray, Jinhua Wang, Ying Qu, Myung Shin Sim, Jaime Shamonki, Sanjay P. Bagaria, Xing Ye, Bingya Liu, David Elashoff, Dave S. Hoon, Michael A. Walter, John W. Martens, Andrea L. Richardson, Armando E. Giuliano, Xiaojiang Cui

Research output: Contribution to journalArticle

148 Citations (Scopus)

Abstract

Gene expression signatures for a basal-like breast cancer (BLBC) subtype have been associated with poor clinical outcomes, but a molecular basis for this disease remains unclear. Here, we report overexpression of the transcription factor FOXC1 as a consistent feature of BLBC compared with other molecular subtypes of breast cancer. Elevated FOXC1 expression predicted poor overall survival in BLBC (P = 0.0001), independently of other clinicopathologic prognostic factors including lymph node status, along with a higher incidence of brain metastasis (P = 0.02) and a shorter brain metastasis-free survival in lymph node-negative patients (P < 0.0001). Ectopic overexpression of FOXC1 in breast cancer cells increased cell proliferation, migration, and invasion, whereas shRNA-mediated FOXC1 knockdown yielded opposite effects. Our findings identify FOXC1 as a theranostic biomarker that is specific for BLBC, offering not only a potential prognostic candidate but also a potential molecular therapeutic target in this breast cancer subtype.

Original languageEnglish (US)
Pages (from-to)3870-3876
Number of pages7
JournalCancer Research
Volume70
Issue number10
DOIs
StatePublished - May 15 2010
Externally publishedYes

Fingerprint

Biomarkers
Breast Neoplasms
Lymph Nodes
Neoplasm Metastasis
Survival
Brain
Transcriptome
Small Interfering RNA
Cell Movement
Transcription Factors
Cell Proliferation
Incidence

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Ray, P. S., Wang, J., Qu, Y., Sim, M. S., Shamonki, J., Bagaria, S. P., ... Cui, X. (2010). FOXC1 is a potential prognostic biomarker with functional significance in basal-like breast cancer. Cancer Research, 70(10), 3870-3876. https://doi.org/10.1158/0008-5472.CAN-09-4120

FOXC1 is a potential prognostic biomarker with functional significance in basal-like breast cancer. / Ray, Partha S.; Wang, Jinhua; Qu, Ying; Sim, Myung Shin; Shamonki, Jaime; Bagaria, Sanjay P.; Ye, Xing; Liu, Bingya; Elashoff, David; Hoon, Dave S.; Walter, Michael A.; Martens, John W.; Richardson, Andrea L.; Giuliano, Armando E.; Cui, Xiaojiang.

In: Cancer Research, Vol. 70, No. 10, 15.05.2010, p. 3870-3876.

Research output: Contribution to journalArticle

Ray, PS, Wang, J, Qu, Y, Sim, MS, Shamonki, J, Bagaria, SP, Ye, X, Liu, B, Elashoff, D, Hoon, DS, Walter, MA, Martens, JW, Richardson, AL, Giuliano, AE & Cui, X 2010, 'FOXC1 is a potential prognostic biomarker with functional significance in basal-like breast cancer', Cancer Research, vol. 70, no. 10, pp. 3870-3876. https://doi.org/10.1158/0008-5472.CAN-09-4120
Ray, Partha S. ; Wang, Jinhua ; Qu, Ying ; Sim, Myung Shin ; Shamonki, Jaime ; Bagaria, Sanjay P. ; Ye, Xing ; Liu, Bingya ; Elashoff, David ; Hoon, Dave S. ; Walter, Michael A. ; Martens, John W. ; Richardson, Andrea L. ; Giuliano, Armando E. ; Cui, Xiaojiang. / FOXC1 is a potential prognostic biomarker with functional significance in basal-like breast cancer. In: Cancer Research. 2010 ; Vol. 70, No. 10. pp. 3870-3876.
@article{8d267d60a3ec4bb188487af2b711fd8b,
title = "FOXC1 is a potential prognostic biomarker with functional significance in basal-like breast cancer",
abstract = "Gene expression signatures for a basal-like breast cancer (BLBC) subtype have been associated with poor clinical outcomes, but a molecular basis for this disease remains unclear. Here, we report overexpression of the transcription factor FOXC1 as a consistent feature of BLBC compared with other molecular subtypes of breast cancer. Elevated FOXC1 expression predicted poor overall survival in BLBC (P = 0.0001), independently of other clinicopathologic prognostic factors including lymph node status, along with a higher incidence of brain metastasis (P = 0.02) and a shorter brain metastasis-free survival in lymph node-negative patients (P < 0.0001). Ectopic overexpression of FOXC1 in breast cancer cells increased cell proliferation, migration, and invasion, whereas shRNA-mediated FOXC1 knockdown yielded opposite effects. Our findings identify FOXC1 as a theranostic biomarker that is specific for BLBC, offering not only a potential prognostic candidate but also a potential molecular therapeutic target in this breast cancer subtype.",
author = "Ray, {Partha S.} and Jinhua Wang and Ying Qu and Sim, {Myung Shin} and Jaime Shamonki and Bagaria, {Sanjay P.} and Xing Ye and Bingya Liu and David Elashoff and Hoon, {Dave S.} and Walter, {Michael A.} and Martens, {John W.} and Richardson, {Andrea L.} and Giuliano, {Armando E.} and Xiaojiang Cui",
year = "2010",
month = "5",
day = "15",
doi = "10.1158/0008-5472.CAN-09-4120",
language = "English (US)",
volume = "70",
pages = "3870--3876",
journal = "Journal of Cancer Research",
issn = "0099-7013",
publisher = "American Association for Cancer Research Inc.",
number = "10",

}

TY - JOUR

T1 - FOXC1 is a potential prognostic biomarker with functional significance in basal-like breast cancer

AU - Ray, Partha S.

AU - Wang, Jinhua

AU - Qu, Ying

AU - Sim, Myung Shin

AU - Shamonki, Jaime

AU - Bagaria, Sanjay P.

AU - Ye, Xing

AU - Liu, Bingya

AU - Elashoff, David

AU - Hoon, Dave S.

AU - Walter, Michael A.

AU - Martens, John W.

AU - Richardson, Andrea L.

AU - Giuliano, Armando E.

AU - Cui, Xiaojiang

PY - 2010/5/15

Y1 - 2010/5/15

N2 - Gene expression signatures for a basal-like breast cancer (BLBC) subtype have been associated with poor clinical outcomes, but a molecular basis for this disease remains unclear. Here, we report overexpression of the transcription factor FOXC1 as a consistent feature of BLBC compared with other molecular subtypes of breast cancer. Elevated FOXC1 expression predicted poor overall survival in BLBC (P = 0.0001), independently of other clinicopathologic prognostic factors including lymph node status, along with a higher incidence of brain metastasis (P = 0.02) and a shorter brain metastasis-free survival in lymph node-negative patients (P < 0.0001). Ectopic overexpression of FOXC1 in breast cancer cells increased cell proliferation, migration, and invasion, whereas shRNA-mediated FOXC1 knockdown yielded opposite effects. Our findings identify FOXC1 as a theranostic biomarker that is specific for BLBC, offering not only a potential prognostic candidate but also a potential molecular therapeutic target in this breast cancer subtype.

AB - Gene expression signatures for a basal-like breast cancer (BLBC) subtype have been associated with poor clinical outcomes, but a molecular basis for this disease remains unclear. Here, we report overexpression of the transcription factor FOXC1 as a consistent feature of BLBC compared with other molecular subtypes of breast cancer. Elevated FOXC1 expression predicted poor overall survival in BLBC (P = 0.0001), independently of other clinicopathologic prognostic factors including lymph node status, along with a higher incidence of brain metastasis (P = 0.02) and a shorter brain metastasis-free survival in lymph node-negative patients (P < 0.0001). Ectopic overexpression of FOXC1 in breast cancer cells increased cell proliferation, migration, and invasion, whereas shRNA-mediated FOXC1 knockdown yielded opposite effects. Our findings identify FOXC1 as a theranostic biomarker that is specific for BLBC, offering not only a potential prognostic candidate but also a potential molecular therapeutic target in this breast cancer subtype.

UR - http://www.scopus.com/inward/record.url?scp=77952821751&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77952821751&partnerID=8YFLogxK

U2 - 10.1158/0008-5472.CAN-09-4120

DO - 10.1158/0008-5472.CAN-09-4120

M3 - Article

C2 - 20406990

AN - SCOPUS:77952821751

VL - 70

SP - 3870

EP - 3876

JO - Journal of Cancer Research

JF - Journal of Cancer Research

SN - 0099-7013

IS - 10

ER -